ABSTRACT
Introduction Hepatitis B virus(HBV) infects about 2 billion people globally and accounts for mortality of about 800,000 from liver cirrhosis and hepatocellular carcinoma. Sub-Saharan Africa accounts for 70% of Human Immunodeficiency Virus (HIV) global burden. HIV/HBV co-infection results in early development of HBV complications, alterations of serological biomarkers of HBV.
Methods Two hundred and fifty patients with HIV/AIDS were screened for HBV and 20 (8%) were identified. Same number of HBV mono-infected individuals were recruited into the study and subsequently, HBV serological profiles which includes HBsAg, HBsAb, HBeAg, HBeAb,HBcAbIgM and HBcAbIgG were assayed using HBV ELISA kits.
Result Mean age of patients in the HBV/HIV cohort was 45.5 years while the HBV mono-infected infected cohort was 30.5 years. Majority of the HBV/HIV co-infected individuals were females (85%). Frequency of HBeAg among HIV/HBV co-infected cohort was 25% and 15% for HBV mono-infected, while the frequency of HBeAb was higher (60%) among cohort of HBV/HIV co-infected patients in comparison with the HBV mono-infected cohorts(50%). Two patients among the HIV/HBV co-infected cohort have the isolated anti-HBcAg serologic pattern.
Conclusion The study broadened the available evidence of comparative serologic profiles of Hepatitis B virus between cohorts of HBV/HIV co-infected individuals and HBV mono-infected patients in Nigeria.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
study was funded by the authors
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The Institutional Review Board(IRB) of the Obafemi Awolowo University Teaching Hospital, Ile-Ife granted ethical approval (reference number: NHREC/27/02/2009a) before study commenced.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The data for this study are available from the corresponding author upon request
